Five-year RFS and OS of E2993 patients by combined protocol-defined and molecular-defined risk assignment
| Combined risk group . | 5-y RFS, % (95% CI) . | 5-y OS, % (95% CI) . |
|---|---|---|
| pLR/mSR | 73.3 (59.8, 89.9) | 87.9 (77.5, 99.8) |
| pLR/mIR | 29.4 (14.1, 61.4) | 31.6 (16.3, 61.2) |
| pLR/mHR | 28.9 (14.7, 56.6) | 36.2 (21.5, 60.9) |
| pHR/mSR | 62.0 (45.2, 85.1) | 53.2 (37.5, 75.6) |
| pHR/mIR | 27.7 (13.8, 55.3) | 42.0 (25.5, 69.4) |
| pHR/mHR | 11.9 (6.23, 22.9) | 12.9 (7.19, 23.1) |
| Combined risk group . | 5-y RFS, % (95% CI) . | 5-y OS, % (95% CI) . |
|---|---|---|
| pLR/mSR | 73.3 (59.8, 89.9) | 87.9 (77.5, 99.8) |
| pLR/mIR | 29.4 (14.1, 61.4) | 31.6 (16.3, 61.2) |
| pLR/mHR | 28.9 (14.7, 56.6) | 36.2 (21.5, 60.9) |
| pHR/mSR | 62.0 (45.2, 85.1) | 53.2 (37.5, 75.6) |
| pHR/mIR | 27.7 (13.8, 55.3) | 42.0 (25.5, 69.4) |
| pHR/mHR | 11.9 (6.23, 22.9) | 12.9 (7.19, 23.1) |